The trailblazing study will use the data from up to 1.4million NHS patients to test whether its shingles vaccine reduces the risk of the degenerative disease, which is the country’s biggest killer. The trailblazing study will use the data from up to 1.4million NHS patients to test whether its shingles vaccine reduces the risk of the degenerative disease, which is the country’s biggest killer.
Does the shingles jab slash your risk of dementia? Drugs giant GSK launches ground-breaking study that could save millions of Brits from developing the disease
